CANF ▲ +1.8% - Can-Fite BioPharma Ltd. $CANF - Can-Fite: Publication Reports Improvement in Decompensated Cirrhosis with Namodenoson and Successful Bridging to Liver Transplantation Can-Fite BioPharma shares rose 1.8% following publication of reports showing that its drug namodenoson improved outcomes in patients with decompensated cirrhosis and enabled successful bridging to liver transplantation. The positive clinical data on the company's lead candidate in liver disease represents progress toward potential commercialization in an area of significant unmet medical need. 09-SEP-2026 07:02 AM ET